Related Experiment Video
Updated: Aug 4, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Selective targeting of glioma via the SCARB2 receptor: transcriptomic, proteomic and in vitro functional validation
Jinchuan Li1, Yi Zhang1, Junjie Zhang1
1Department of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan, China.
Background:
Oncolytic viruses (OVs) achieve selective cytolysis via tumor-specific entry receptor. However, the prevalence of OVs receptors in malignant tumors has not been fully determined yet. Here, we systematically identify and characterize critical cellular entry receptors for clinically relevant OVs, particularly focusing on SCARB2 expression and its potential therapeutic implications for oncolytic Enterovirus A71 (EV-A71) therapy in glioma.
Methods:
A systematic literature review was performed to summarize key entry receptors of major oncolytic viruses. Transcriptomic and proteomic data from TCGA, CPTAC, HPA, GEPIA2, CGGA and clinical databases were analyzed to profile receptor expression and clinical relevance across cancer types, especially glioma. Immunofluorescence and RNAi assays in glioblastoma (GBM) cell lines were conducted to assess SCARB2 localization, expression, and cellular functional roles.
Results:
Pan-cancer analyses revealed widespread overexpression of key viral receptors. SCARB2 significantly was overexpressed in glioma compared to brain tissues. Elevated SCARB2 protein levels were particularly noted in high-grade gliomas. Further in vitro assays confirmed SCARB2 localization primarily at the cell membrane in glioblastoma cells. Additionally, SCARB2 expression correlated with molecular subtype, immune subtype, and tumor-infiltrating lymphocyte composition in gliomas. Functional studies demonstrated that SCARB2 knockdown and EV-A71 infection markedly reduced GBM cell proliferation and enhanced cell apoptosis rate, suggesting its critical role in facilitating viral entry and subsequent antitumor effects.
Conclusions:
SCARB2 serves as a critical cellular receptor for EV-A71-mediated oncolytic activity in glioma. Elevated SCARB2 expression in GBM highlights its potential as both a therapeutic target and predictive biomarker for selecting glioma patients responsive to oncolytic EV-A71 therapy.
Insights
This study identifies SCARB2 as a key receptor for oncolytic Enterovirus A71 (EV-A71) in glioma. Elevated SCARB2 expression in glioblastoma suggests its potential as a therapeutic target and biomarker for EV-A71 oncolytic virotherapy.
Area of Science:
- Oncolytic virotherapy
- Cancer biology
- Molecular virology
Background:
- Oncolytic viruses (OVs) target tumors via specific receptors, but their prevalence is often unknown.
- This study investigates SCARB2 as a critical receptor for oncolytic Enterovirus A71 (EV-A71) in glioma.
Purpose of the Study:
- To systematically identify and characterize cellular entry receptors for clinically relevant OVs.
- To evaluate SCARB2 expression and its therapeutic implications for EV-A71 therapy in glioma.
Main Methods:
- Systematic literature review of OV entry receptors.
- Analysis of transcriptomic and proteomic data (TCGA, CPTAC, HPA, GEPIA2, CGGA).
- In vitro assays (immunofluorescence, RNAi) in glioblastoma (GBM) cell lines.
Main Results:
- SCARB2 is significantly overexpressed in glioma, especially high-grade gliomas, compared to normal brain tissue.
- SCARB2 is located at the cell membrane in GBM cells and its expression correlates with glioma subtypes and immune infiltration.
- SCARB2 knockdown and EV-A71 infection reduced GBM cell proliferation and increased apoptosis.
Conclusions:
- SCARB2 is a critical receptor mediating EV-A71 oncolytic activity in glioma.
- Elevated SCARB2 in GBM presents a potential therapeutic target and predictive biomarker for EV-A71 virotherapy.
